Diagnostic potential of urinary PENK methylation for bladder cancer in patients with hematuria: insights from a prospective and multi-institutional study
Dai Koguchi, Izuru Shiba, Yutaka Shiono, Kazumasa Matsumoto · 2026
Read Diagnostic potential of urinary PENK methylation for bladder cancer in patients with hematuria: insights from a prospective and multi-institutional study by Dai Koguchi, Izuru Shiba, Yutaka Shiono, Kazumasa Matsumoto (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13263808.txt.
Description
Dai Koguchi and colleagues commented in 2026 on a urine test that could spare many patients with bloody urine an invasive bladder inspection. The test reads methylation of the PENK gene in urine, a chemical switch that silences the gene in several cancers. Their commentary examines a large prospective study run across ten Korean institutions.
That study enrolled patients with hematuria prospectively and sized its cohort from pilot accuracy figures. Earlier single-center work had hinted the marker performs best for high-grade and advanced tumors, precisely the dangerous ones. The commentators weigh the design strengths against what clinics would need before adopting the test. They frame urinary methylation testing as a credible route to fewer unnecessary cystoscopies. Remaining questions include cost, workflow, and how the marker combines with existing tools.
Catalog record
| CREATOR | Dai Koguchi, Izuru Shiba, Yutaka Shiono, Kazumasa Matsumoto |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |